17 research outputs found
Effect of atorvastatin on systolic and diastolic function in patients with heart failure with reduced ejection fraction (HFrEF)
Aim To investigate the benefit of high-dose lipophilic statin therapy on cardiac remodelling, function and progression of heart failure (HF) in patients with ischemic heart disease.
Methods A total of 80 patients with ischemic HF diagnosis were
followed during 6 months, and they were divided in two groups.
First group (n=40) was treated by high-dose lipophilic statin therapy (atorvastatin 40 mg) and conventional therapy for HF, while
the second group (n=40) had no atorvastatin in the therapy.
Results In the beginning of study, from all of the observed parameters, only the ratio of flow rates in early and late diastole (E/A
ratio) differed between the test groups (p=0.007). After six months,
a statistically significant increase in left ventricular end-diastolic
diameter (LVIDD) in patients who had not been treated with atorvastatin was found. In the patients treated with atorvastatin, there
was a significant reduction in basal right ventricle diameter in diastole and systole (p<0.001 and p<0.001, respectively), and in tricuspid annular plane systolic excursion (TAPSE) (p<0.001); there
was a reduction in LVIDD (p<0.001), and an increase of ejection
fraction of the left ventricle according to Teicholtz and Simpson
(p<0.001 and p<0.001, respectively). Also, there was an increase
of deceleration time of early diastolic velocity (DTE) (p<0.05) and
a decrease of isovolumic relaxation time (IVRT) (p<0.001).
Conclusion The reduction in the right and left ventricle diameters
was noted after the six-month atorvastatin therapy. Atorvastatin in
the therapy resulted in increased EFLV and better systolic function
and should be a part of a therapeutic modality of HF